Secreted Sars-Cov-2 Encoded ORF8 Protein Stimulates Pro-Inflammatory Cytokines and Predicts Severe Clinical Outcome
Michelle K. Manske(Mayo Clinic in Arizona), Thomas E. Witzig(WinnMed), Jonas Paludo(WinnMed), Jithma P. Abeykoon(Mayo Clinic), Xiaosheng Wu(Mayo Clinic), Taylor L. Witter(Mayo Clinic), Andrew D. Badley(Mayo Clinic), Kimberly Gwin(Mayo Clinic in Arizona), Stephen M. Ansell(Mayo Clinic), Surendra Dasari(Mayo Clinic in Arizona), Yue Yu(Harbin Medical University), Xinyi Tang, Gordon Ruan(Mayo Clinic in Arizona), Kevin E. Nowakowski(Mayo Clinic in Arizona), Matthew J. Schellenberg(Mayo Clinic)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
|Proceedings of the National Academy of Sciences|2012|990